Endocrinology

Thyroid Cancer

Questions discussed in this category

For patients with low risk, differentiated thyroid cancer, how do you navigate the decision between less aggressive treatments, such as lobectomy alone without radioactive iodine, and more aggressive strategies?

1 Answer available

What factors aside from progression do you consider most important in determining whether a patient with metastatic papillary thyroid carcinoma is radioactive iodine refractory?

What is your evaluation approach for RAI response? What cumulative dose do you use in practice for deciding a patient is RAI refractory?

2 Answers available

Does papillary thyroid cancer with extensive squamous differentiation require specialized treatment beyond RAI and TSH suppression?

Patient has 1.1 cm follicular variant PTC with extensive squamous differentiation. Neg 2/2 nodes. Already had total thyroidectomy. Would you recommend...

1 Answer available

Is tall cell variant papillary thyroid cancer automatically categorized as intermediate risk regardless of other histopathological features and should consequently be treated with RAI?

A female in her early 70s, total thyroidectomy, left 1.4 cm and right 0.7 cm tall cell variant papillary thyroid cancer with clear margins and negativ...

1 Answer available

What is the clinical significance of positive anti-thyroid antibodies in a patient that is post-thyroidectomy?

1 Answer available

How do you approach a young patient with metastatic poorly differentiated thyroid cancer with rhabdoid/non-anaplastic features?

4 Answers available

Is dosimetry more important than preparation (ie rhTSH versus THW) when treating thyroid cancer with radioactive iodine therapy?

1 Answer available

What is the role of radiation therapy for an elderly patient with medullary thyroid cancer who is not a surgical candidate?

What techniques and doses would you prescribe to the primary and regional nodes?

1 Answer available

When would you offer post-operative concurrent chemoradiation in anaplastic thyroid cancer?

Would you consider it for a patient with good PS but with limited metastatic disease? What dose fractionation would you prefer?